GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) » Definitions » Price-to-Owner-Earnings

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Price-to-Owner-Earnings : (As of Jun. 07, 2024)


View and export this data going back to 2016. Start your Free Trial

What is ExpreS2ion Biotech Holding AB Price-to-Owner-Earnings?

As of today (2024-06-07), ExpreS2ion Biotech Holding AB's share price is kr1.15. ExpreS2ion Biotech Holding AB does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for ExpreS2ion Biotech Holding AB's Price-to-Owner-Earnings or its related term are showing as below:


OSTO:EXPRS2's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.745
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-07), ExpreS2ion Biotech Holding AB's share price is kr1.15. ExpreS2ion Biotech Holding AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-1.35. Therefore, ExpreS2ion Biotech Holding AB's PE Ratio for today is At Loss.

As of today (2024-06-07), ExpreS2ion Biotech Holding AB's share price is kr1.15. ExpreS2ion Biotech Holding AB's EPS without NRI for the trailing twelve months (TTM) ended in was kr-1.35. Therefore, ExpreS2ion Biotech Holding AB's PE Ratio without NRI for today is At Loss.


ExpreS2ion Biotech Holding AB Price-to-Owner-Earnings Historical Data

The historical data trend for ExpreS2ion Biotech Holding AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ExpreS2ion Biotech Holding AB Price-to-Owner-Earnings Chart

ExpreS2ion Biotech Holding AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ExpreS2ion Biotech Holding AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ExpreS2ion Biotech Holding AB's Price-to-Owner-Earnings

For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ExpreS2ion Biotech Holding AB's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where ExpreS2ion Biotech Holding AB's Price-to-Owner-Earnings falls into.



ExpreS2ion Biotech Holding AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

ExpreS2ion Biotech Holding AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.15/-0.90
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ExpreS2ion Biotech Holding AB  (OSTO:EXPRS2) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


ExpreS2ion Biotech Holding AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of ExpreS2ion Biotech Holding AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Business Description

Traded in Other Exchanges
Address
c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, S-252 25
ExpreS2ion Biotech Holding AB has developed a technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. The company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with research institutions and companies.

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Headlines

No Headlines